Australia's most trusted
source of pharma news
Thursday, 06 November 2025
Posted 24 August 2023 PM
Johnson & Johnson has finalised its separation from its healthcare business, with shareholders flocking to exchange their J&J shares for holdings in the new company, Kenvue.
The pharma giant ran an offer for its shareholders to swap each of their shares in J&J for 8.0324 shares of Kenvue common stock, with the offer being heavily over-subscribed. Only 23.86 per cent of J&J shares tended for exchange were accepted in the offer.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.